33 / 43
Advanced NSCLC with Checkpoint inhibitors
Trial
Drug
Genomic
source
Platform
Read
Pairs
TMB Cut-points
CheckMate 026
1
Nivo
Tissue
WES
llumina HiSeq
80M
≥243 mut/tm
FIR/BIRCH/
POPLAR
2
Atezo
Tissue
F1
Ilumina HiSeq
20M ≥9.9 mut/tm (median) or
≥16.2 mut/Mb (75% Q)
KEYNOTE 001
4
Pembro
Tissue
WES
-
≥209 mut/tm
KEYNOTE
012/028
5
Pembro
Tissue
WES
-
≥102 mut/tm
POPLAR (training)/
OAK (Validation)
5
Atezo
Blood
394 gene-based NGS
assay
≥16 mut/tm
1.- Peters et al. AACR 2017; 2. Kowanetz et al. WCLC 2016; 3. Rizvi ,Science 2015 ; 4. Critescu R. et al ASCO-SITC 2017; 5. Gadara ESMO 2017
First Challenge: Harmonization of practices between platforms